Pharmaceutical Executive

Pharmaceutical Executive Podcast

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

Subscribe Listen in podnod RSS feed Show website

414 episodes
Updated Today

Episodes414

Newest first

Oct 17, 2025 · 3 min
Pharmaceutical Executive Daily: EMD Serono’s Agreement with US Government
In today’s Pharmaceutical Executive Daily, we explore how antibody-drug conjugate collaborations are moving beyond oncology into autoimmune diseases, EMD Serono’s agreement with the Trump administration to expand access to in vitro fertilization therapies, and how the obesity treatment market is evolving after GLP-1 dominance.
Oct 16, 2025 · 2 min
Pharmaceutical Executive Daily: Rethinking Workforce Development
In today’s Pharmaceutical Executive Daily, we explore how pharma leaders are rethinking workforce development at the executive level, the industry’s growing investment in rare disease therapies, and emerging opportunities and challenges in psychiatric drug development.
Oct 15, 2025 · 2 min
Pharmaceutical Executive Daily: Johnson & Johnson Separating Its Orthopedics Unit
In today’s Pharmaceutical Executive Daily, we explore Johnson & Johnson’s plan to separate its orthopaedics division into a standalone company, the global implications of the Most Favored Nation drug pricing proposal, and strategies helping small biotechs reach market faster.
Oct 14, 2025 · 3 min
Pharmaceutical Executive Daily: Direct-To-Consumer Trends
In today’s Pharmaceutical Executive Daily, we cover Takeda’s new multi-year research collaboration with Nabla Bio, how tariff and pricing pressures are driving pharma toward direct-to-consumer strategies, and reports of AstraZeneca reaching an agreement with the Trump administration.
Oct 14, 2025 · 10 min
Advancing Neuroscience and Rare Disease Innovation
Acadia Pharmaceuticals’ CEO Catherine Owen Adams discusses the current climate in R&D and details her leadership style.
Oct 13, 2025 · 2 min
Pharmaceutical Executive Daily: Policy Whiplash
In today’s Pharmaceutical Executive Daily, we cover Ypsomed’s new North Carolina manufacturing site, how pharma leaders are maintaining strategic clarity amid policy whiplash, and Excellergy’s $70 million Series A launch to advance its trifunctional immunotherapy platform.
Oct 10, 2025 · 2 min
Pharmaceutical Executive Daily: Most Favored Nation Order's Evolving Landscape
In today’s Pharmaceutical Executive Daily, we cover Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics, ongoing legal and market implications of the Most Favored Nation drug pricing proposal, and the FDA’s approval of Libtayo as an adjuvant therapy for cutaneous squamous cell carcinoma.
Oct 9, 2025 · 2 min
Pharmaceutical Executive Daily: Why DSCSA Compliance is Only The Beginning
In today’s Pharmaceutical Executive Daily, we cover the FDA’s approval of Johnson & Johnson’s Simponi for pediatric ulcerative colitis, why DSCSA compliance is only the beginning of pharma supply chain modernization, and the agency’s approval of Jascayd for idiopathic pulmonary fibrosis.
Oct 8, 2025 · 3 min
Pharmaceutical Executive Daily: Amgen Launches New Direct-To-Consumer Platform
In today’s Pharmaceutical Executive Daily, we explore why medical AI success depends on more than algorithms, Amgen’s launch of its new direct-to-consumer platform AmgenNow, and AstraZeneca’s multi-target research partnership with Algen.
Oct 7, 2025 · 2 min
Pharmaceutical Executive Daily: FDA Lifts Clinical Hold on NUZ-001
In today’s Pharmaceutical Executive Daily, we cover the FDA lifting its clinical hold on Neurizon Therapeutics’ lead program Nuz-001, the agency’s export ban on Sun Pharma’s Halol facility, and new insights on how small biotechs can better navigate regulatory and market complexities.
Oct 6, 2025 · 2 min
Pharmaceutical Executive Daily: Updated Vaccine Recommendations
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry. In today’s Pharmaceutical Executive Daily, we cover lessons from FDA complete response letters shaping CMC strategy in cell and gene therapy, Takeda’s decision to discontinue its cell therapy research programs, and the CDC’s latest update to COVID-19 vaccination recommendations.
Oct 3, 2025 · 2 min
Pharmaceutical Executive Daily: FDA's new Fast-Track Review
In today’s Pharmaceutical Executive Daily, we cover the FDA’s new fast-track review program for U.S.-made generics, Novartis’ FDA approval of Rhapsido for chronic spontaneous urticaria, and Halozyme’s $750 million acquisition of Elektrofi to strengthen drug delivery innovation.
Oct 2, 2025 · 2 min
Pharmaceutical Executive Daily: President Trump Pauses Tariff Plan
Stay informed on key pharmaceutical news, including tariff updates, FDA shutdown risks, and insights from recent cell and gene therapy reviews.
Oct 1, 2025 · 2 min
Pharmaceutical Executive Daily: Novo Nordisk Resubmits BLA for Awiqli
In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s resubmission of its BLA for Awiqli, the FDA’s approval of Kedrion’s Qivigy for primary humoral immunodeficiency, and Eli Lilly’s decision to halt development of a muscle-preserving weight-loss therapy.
Sep 30, 2025 · 2 min
Pharmaceutical Executive Daily: September 30, 2025
In today’s Pharmaceutical Executive Daily, we cover AbbVie’s new API manufacturing site in Illinois, AstraZeneca’s plan to harmonize its global stock exchange listings, and reports that President Trump will announce a government-run direct-to-patient drug purchasing website.
Sep 29, 2025 · 2 min
Pharmaceutical Executive Daily: September 29, 2025
In today’s Pharmaceutical Executive Daily, we cover the impact of Novo Nordisk layoffs on its hometown in Denmark, GSK’s appointment of Luke Miels as its next CEO, and the FDA’s approval of Regeneron’s Evkeeza for children with homozygous familial hypercholesterolemia.
Sep 26, 2025 · 2 min
Pharmaceutical Executive Daily: September 26, 2025
In today’s Pharmaceutical Executive Daily, we cover the White House’s push for a Most Favored Nation drug pricing model, the FDA’s approval of Eli Lilly’s Inluriyo for ESR1-mutated metastatic breast cancer, and President Trump’s call for steep tariffs on branded pharmaceuticals
Sep 25, 2025 · 2 min
Pharmaceutical Executive Daily: September 25, 2025
In today’s Pharmaceutical Executive Daily, we cover Glenmark’s billion-dollar exclusive licensing deal with Hengrui, Harmony Biosciences’ trial setback for Zygel, and the CDC’s unanimous vote to broaden COVID-19 vaccine recommendations.
Sep 24, 2025 · 2 min
Pharmaceutical Executive Daily: September 24, 2025
In today’s Pharmaceutical Executive Daily, we cover the market reaction to Trump’s Tylenol–autism claim, the FDA’s complete response letter to Scholar Rock for its spinal muscular atrophy treatment, and a closer look at the state of evidence linking Tylenol use and autism risk.
Sep 23, 2025 · 2 min
Pharmaceutical Executive Daily: September 23, 2025
In today’s Pharmaceutical Executive Daily, we cover GSK’s supplemental application to update the label for Leucovorin, the FDA’s complete response letter to Otsuka and Lundbeck’s sNDA for Rexulti, and the medical community’s response to former President Trump’s claims linking Tylenol use to autism risk.